• Content
  • Search
  • Navigation
  • Sitemap
  • About us
    • About us
    • Who we are
    • Our model
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Portfolio data
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • AGTC
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
      • Kesmalea Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • Neogene Therapeutics
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chair, SIML
    • Our approach to sustainability reporting
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
      • Sustainability within the Syncona portfolio
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
      • Syncona TCFD disclosure
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment proposition
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact

Portfolio data

Browse all portfolio data news

    Latest portfolio data news

    Show news from
    • all companies
    • all Cell therapy companies
    • Autolus
    • all Gene therapy companies
    • all Biologics companies
    • all Small molecule companies
    03.11.22

    Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

    • Cell therapy
    • Autolus
    13.12.21

    Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

    • Cell therapy
    • Autolus
    01.09.21

    Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology

    • Operating News
    • Cell therapy
    • Autolus
    30.11.20

    Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine

    • Operating News
    • Cell therapy
    • Autolus
    12.06.20

    Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress

    • Operating News
    • Cell therapy
    • Autolus
    29.05.20

    Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program

    • Operating News
    • Cell therapy
    • Autolus
    Load more

    Sign-up for company news alerts

    Get the latest RNS, company news, share price information and results from Syncona

    • RNS alerts
    • Company alerts

    Syncona Investment Management Limited
    2nd Floor
    8 Bloomsbury Street
    London
    WC1B 3SR
    contact@synconaltd.com

    • About us
    • Our people
    • Portfolio
    • Sustainability
    • News and Insights
    • Investors
    • Contact
    • Copyright © Syncona 2023
    • Accessibility
    • Privacy & cookies
    • Employee privacy notice
    • Third party privacy notice
    • Regulatory publications
    • Modern Slavery Statement

    Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
    Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

    Designed & built by SampsonMay
    • About us
      • About us
      • Who we are
      • Our model
      • Data driven investment process
      • Our purpose, culture and values
      • Our history
    • Our people
      • Our people
      • Board of directors
    • Portfolio
      • Portfolio
      • Portfolio data
      • Cell therapy
        • Overview
        • Autolus
        • Achilles Therapeutics
        • Quell Therapeutics
        • Resolution Therapeutics
        • Clade Therapeutics
      • Gene therapy
        • Overview
        • Freeline Therapeutics
        • AGTC
        • SwanBio Therapeutics
        • Purespring Therapeutics
      • Biologics
        • Overview
        • Anaveon
      • Small molecule
        • Overview
        • OMass Therapeutics
        • Kesmalea Therapeutics
      • Previous investments
        • Overview
        • Gyroscope Therapeutics
        • Blue Earth
        • Nightstar
        • Neogene Therapeutics
        • 14MG
        • Azeria Therapeutics
    • Sustainability
      • Sustainability
      • Message from Chair, SIML
      • Our approach to sustainability reporting
      • Our social impact
      • Responsible investor and partner
        • Overview
        • Responsible investment process
        • A responsible partner
        • Sustainability within the Syncona portfolio
      • Inspiring and empowering our people
      • Responsible and ethical business
        • Overview
        • Environment
        • Syncona TCFD disclosure
      • Syncona’s approach to charity
        • Overview
        • The Syncona Foundation
      • Sustainability policies
    • News and Insights
    • Investors
      • Investors
      • Investment proposition
      • KPIs
      • Results and presentations
      • RNS and inside information
      • Share price centre
      • Governance
        • Overview
        • Our Committees
        • How we communicate with our stakeholders
      • Regulatory publications
      • Financial calendar
      • Analysts and advisers
      • Shareholder information
        • Overview
        • Shareholder documents
      • FAQs
    • Contact
    GBX 177.20
    Change: -3.20 (-1.77%)

    Search